Citation Information :
Sivaradjy M, Gunalan A, Priyadarshi K, Madigubba H, Rajshekar D, Sastry AS. Increasing Trend of Vancomycin-resistant Enterococci Bacteremia in a Tertiary Care Hospital of South India: A Three-year Prospective Study. Indian J Crit Care Med 2021; 25 (8):881-885.
Introduction: Vancomycin-resistant enterococci (VRE) are emerging as an important multidrug-resistant pathogen causing nosocomial infections, predominantly bacteremia and urinary tract infections. VRE bacteremia has caused a significant increase in the duration of the hospital stay and mortality and had caused high public health threat due to limited treatment options.
Materials and methods: Between October 2017 and September 2020, all consecutive patients with culture-proven bloodstream infection with Enterococcus species, isolated for the first time, were included in the study. A total of 427 Enterococcus species were identified, and antimicrobial susceptibility tests were performed and interpreted using Clinical and Laboratory Standard Institute guidelines.
Results: Of the total 427 Enterococcus species isolated, 63 (45.6%) were VRE. Among them, 51/63 (81%) were Enterococcus faecium (E. faecium) and 5/63 (8%) were Enterococcus faecalis. There was an increased trend of VRE rate in the bloodstream infections of 6.12% (2018), 13.2% (2019), and 19.2% (2020). The majority of the VRE patients [43/63 (68%)] were admitted to the intensive care units (ICUs). Vancomycin A (VanA) is the most common phenotype isolated from 51/63(81%) patients.
Conclusion: This increasing trend of VRE bacteremia is a red alert to the clinicians and the infection control practitioners, so that strict antibiotic policies and proper adherence to the infection control practices can be initiated to reduce the VRE rate.
Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B, Leclercq R, et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001–08. J Antimicrob Chemother 2011;66(4):713–721. DOI: 10.1093/jac/dkq524.
Praharaj I, Sujatha S, Parija SC. Phenotypic and genotypic characterization of vancomycin resistant Enterococcus isolates from clinical specimens. Indian J Med Res 2013;138(4):549–556. PMID: 24434263.
Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006;42(Suppl. 1):S25–S34. DOI: 10.1086/491711.
Purohit G, Gaind R, Dawar R, Verma PK, Aggarwal KC, Sardana R, et al. Characterization of Vancomycin Resistant Enterococci in hospitalized patients and role of gut colonization. J Clin Diagn Res 2017;11:5. DOI: 10.7860/JCDR/2017/25988.10548.
Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization 2017;27:318–327. DOI: 10.1016/S1473-3099(17)30753-3.
Centers for Disease Control and Prevention. Vancomycin-resistant enterococci (VRE) in healthcare settings.
Ayobami O, Willrich N, Reuss A, Eckmanns T, Markwart R. The ongoing challenge of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Europe: an epidemiological analysis of bloodstream infections. Emerg Microbes Infect 2020;9(1):1180–1193. DOI: 10.1080/22221751.2020.1769500.
Vidyalakshmi P, Ramasubramanian V, Nambi Ps, Gopalakrishnan R, Ghafur Ka, Thirunarayana M. Clinical, epidemiological, and microbiological profile of patients with vancomycin-resistant Enterococci from a Tertiary Care Hospital. J Global Infect Dis 2012;4(2):137. DOI: 10.4103/0974-777X.96784.
Piezzi V, Gasser M, Atkinson A, Kronenberg A, Vuichard-Gysin D, Harbarth S, et al. Increasing proportion of vancomycin resistance among enterococcal bacteremias in Switzerland: a 6-year nation-wide surveillance, 2013 to 2018. Euro Surveill 2020;25(35):1900575. DOI: 10.2807/1560-7917.ES.2020.25.35.1900575.
CLSI, Clinical and Laboratory Standard Institute. Clinical and Laboratory Standards Institute CLSI document: performance standard for antimicrobial susceptibility testing; informational supplement M100-S21.
Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996;156(13):1458–1462. DOI:10.1128/cmr.13.4. 686-707.2000
Xu X, Lin D, Yan G, Ye X, Wu S, Guo Y, et al. vanM, A new glycopeptide resistance gene cluster found in Enterococcus faecium. Antimicrob Agents Chemother 2010;54(11):4643–4647. DOI: 10.1128/AAC. 01710-09.
Faron ML, Ledeboer NA, Buchan BW. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin-resistant enterococcus in the health care setting. J Clin Microbiol 2016;54(10):2436–2447. DOI: 10.1128/JCM.00211-16.
Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti-infect Ther 2014;12(10):1221–1236. DOI: 10.1586/14787210.2014.956092.
Khandelwal N, Panwala T, Patel JS. Prevalence of enterococcus species and its vancomycin resistance pattern in a Tertiary Care Hospital, Surat, Gujarat, India: a growing threat. Int J Recent Sci Res 2020;11(7):3. DOI: 10.24327/ijrsr.2020.1107.5480.
Deshpande VR, Karmarkar MG, Mehta PR. Prevalence of multidrug-resistant enterococci in a tertiary care hospital in Mumbai, India. J Infect Dev Ctries 2013;7(02):155–158. DOI: 10.3855/jidc.3018.
Gastmeier P, Schroder C, Behnke M, Meyer E, Geffers C. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother 2014;69(6):1660–1664. DOI: 10.1093/jac/dku035.
Sohn KM. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis 2013;17(4):e240–e246. DOI: 10.1016/j.ijid.2012.09.019.
Mathis B, Haïne M, Girard R, Bonnefoy M. Risk factors for vancomycin-resistant enterococcus acquisition during a large outbreak in patients aged 65 years and older. BMC Geriatr 2019;19(1):377. DOI: 10.1186/s12877-019-1398-2.
Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 2002;35(10):1139–1146. DOI: 10.1086/342904.
Fridkin SK, Edwards JR, Courval JM, Hill H, Tenover FC, Lawton R, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001;135(3):175–183. DOI: 10.7326/0003-4819-135-3-200108070-00009.
Moemen D, Tawfeek D, Badawy W. Healthcare-associated vancomycin resistant Enterococcus faecium infections in the Mansoura University Hospitals intensive care units, Egypt. Braz J Microbiol 2015;46(3): 777–783. DOI: 10.1590/S1517-838246320140403.
Monteserin N, Larson E. Temporal trends and risk factors for healthcare-associated vancomycin-resistant enterococci in adults. J Hosp Infect 2016;94(3):236–241. DOI: 10.1016/j.jhin.2016.07.023.
Remschmidt C, Schröder C, Behnke M, Gastmeier P, Geffers C, Kramer TS. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany − 10 years of surveillance. Antimicrob Resist Infect Control 2018;7(1):54. DOI: 10.1186/s13756-018-0353-x.
Moosavian M, Ghadri H, Samli Z. Molecular detection of vanA and vanB genes among vancomycin-resistant enterococci in ICU-hospitalized patients in Ahvaz in southwest of Iran. Infect Drug Resist 2018;11:2269–2275. DOI: 10.2147/IDR.S177886.
Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control 1995;23(2):87–94. DOI: 10.1016/0196-6553(95)90104-3.